Pharmacologic treatment of acute kidney injury: Why drugs haven't worked and what is on the horizon

Sang Kyung Jo, Mitchell H. Rosner, Mark D. Okusa

Research output: Contribution to journalShort survey

172 Citations (Scopus)

Abstract

Current strategies to limit the extent of injury in acute renal failure are based on extensive studies that identified cellular and molecular mechanisms of acute kidney injury. Despite successes in various animal models, translation to human studies has failed or studies are inconclusive. This review describes past failures and barriers to successful clinical trials. It also focuses on promising preclinical studies using novel compounds that currently are in or close to human investigation. Implementation of previous or novel compounds in well-designed clinical trials provides hope for the successful treatment of this devastating disorder.

Original languageEnglish
Pages (from-to)356-365
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Volume2
Issue number2
DOIs
Publication statusPublished - 2007 Mar 1
Externally publishedYes

Fingerprint

Acute Kidney Injury
Clinical Trials
Pharmaceutical Preparations
Animal Models
Wounds and Injuries

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Pharmacologic treatment of acute kidney injury : Why drugs haven't worked and what is on the horizon. / Jo, Sang Kyung; Rosner, Mitchell H.; Okusa, Mark D.

In: Clinical Journal of the American Society of Nephrology, Vol. 2, No. 2, 01.03.2007, p. 356-365.

Research output: Contribution to journalShort survey

@article{d8cb864ad8ea4a2e8bb897e4f6a5a450,
title = "Pharmacologic treatment of acute kidney injury: Why drugs haven't worked and what is on the horizon",
abstract = "Current strategies to limit the extent of injury in acute renal failure are based on extensive studies that identified cellular and molecular mechanisms of acute kidney injury. Despite successes in various animal models, translation to human studies has failed or studies are inconclusive. This review describes past failures and barriers to successful clinical trials. It also focuses on promising preclinical studies using novel compounds that currently are in or close to human investigation. Implementation of previous or novel compounds in well-designed clinical trials provides hope for the successful treatment of this devastating disorder.",
author = "Jo, {Sang Kyung} and Rosner, {Mitchell H.} and Okusa, {Mark D.}",
year = "2007",
month = "3",
day = "1",
doi = "10.2215/CJN.03280906",
language = "English",
volume = "2",
pages = "356--365",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - Pharmacologic treatment of acute kidney injury

T2 - Why drugs haven't worked and what is on the horizon

AU - Jo, Sang Kyung

AU - Rosner, Mitchell H.

AU - Okusa, Mark D.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Current strategies to limit the extent of injury in acute renal failure are based on extensive studies that identified cellular and molecular mechanisms of acute kidney injury. Despite successes in various animal models, translation to human studies has failed or studies are inconclusive. This review describes past failures and barriers to successful clinical trials. It also focuses on promising preclinical studies using novel compounds that currently are in or close to human investigation. Implementation of previous or novel compounds in well-designed clinical trials provides hope for the successful treatment of this devastating disorder.

AB - Current strategies to limit the extent of injury in acute renal failure are based on extensive studies that identified cellular and molecular mechanisms of acute kidney injury. Despite successes in various animal models, translation to human studies has failed or studies are inconclusive. This review describes past failures and barriers to successful clinical trials. It also focuses on promising preclinical studies using novel compounds that currently are in or close to human investigation. Implementation of previous or novel compounds in well-designed clinical trials provides hope for the successful treatment of this devastating disorder.

UR - http://www.scopus.com/inward/record.url?scp=34548438633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548438633&partnerID=8YFLogxK

U2 - 10.2215/CJN.03280906

DO - 10.2215/CJN.03280906

M3 - Short survey

C2 - 17699435

AN - SCOPUS:34548438633

VL - 2

SP - 356

EP - 365

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 2

ER -